In vitro, FABP7 enhances CRC cell proliferation and inhibits apoptosis via activation of the MEK/ERK signalling pathway, while its knockdown suppressed tumour growth in vivo and in vitro, implicating it as a potential therapeutic target in CRC pathophysiology (Table 11) [141]. Here, MAP2K7 is linked to colorectal carcinoma.